O’Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L. and Tendler, C. (2004) CAELYX Breast Cancer Study Group. Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX/Doxil) versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer. Annals of Oncology, 15, 440-449.
https://doi.org/10.1093/annonc/mdh097

has been cited by the following article:

• TITLE: Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer

  AUTHORS: Salah Mabrouk Khallaf, Jasmine Roshdy, Abeer Ibrahim

  KEYWORDS: Metastatic Breast, Pegylated Liposomal Doxorubicin, De Novo, Biological Subtypes, Chemosensitivity

  JOURNAL NAME: Advances in Breast Cancer Research, Vol.9 No.2, April 10, 2020

  ABSTRACT: Purpose:The treatment of advanced breast cancer (ABC) is still challenging aiming mainly to improve or maintain the quality of life. The efficacy of pegylated liposomal doxorubicin (PLD) was proven in patients with ABC.Because its expensive treatmentthere is a great need to find the predictive factors for the clinical outcome of PLD.Our purpose was to evaluate the factors whichwould affect the clinical outcomes in patients receiving PLD for advanced breast cancer. Methods: Retrospectively, we studied the medical records of 60 eligible patients during the period of seven years (Jan.2011-Dec.2017).All patientswere treated in Medical Oncology Department, South Egypt Cancer Institute, AssiutUniversity,Egypt. We included only patients with visceral metastasis who received at least 2 cycles of PLD and had radiological assessment after that. Clinical benefit rate of PLD and survival outcome were assessed and correlated with patients and diseasecharacteristic. Results:The majority of patients had a performance status grade II (81.7%), recurrent disease (86.7%), more than one metastatic site (83.3%), and chemoresistance to previous anthracycline (75%).The clinical benefit rate (CBR) to PDL was 30%. We found statisticalsignificant association between higher CBR and biological subtypes (p0.001), type of metastatic breast disease (p=0.003), chemosensitivity to anthracycline (p0.001), and the number of previous lines of chemotherapy (p=0.041).The median progression-free survival (PFS) was five months. There was a statistically-significant improvement of PFS among patients with anthracycline-sensitive tumors compared to those with anthracycline-resistant tumors (10 months vs. 5 months, respectively, p=0.004). The most common toxicity was palmar-plantar erythrodysesthesia (28% for all grade and 9% for grade 3 or more). There was no severe cardiotoxicity or treatment-related death.Conclusion:Pegylated liposomal doxorubicin appears to be more effective in patientswith (luminal B with Her2neupositive, triple-negative and in her2neu amplified), also we noticed that de novo metastatic disease, patient who are not heavily pretreated tumors and patients with the anthracycline-sensitive tumor get more benefit from PLD than others.